Acutus Medical (AFIB) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acutus Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AFIB shares.
View AFIB analyst ratings or view top-rated stocks.

2 brokerages have issued twelve-month target prices for Acutus Medical's shares. Their AFIB share price forecasts range from $1.50 to $2.50. On average, they anticipate the company's share price to reach $2.00 in the next year. This suggests a possible upside of 136.4% from the stock's current price.
View analysts price targets for AFIB or view top-rated stocks among Wall Street analysts.

Acutus Medical's stock was trading at $1.15 on January 1st, 2023. Since then, AFIB shares have decreased by 26.4% and is now trading at $0.8460.
View the best growth stocks for 2023 here.

Acutus Medical saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 493,200 shares, an increase of 6.3% from the April 30th total of 463,800 shares. Based on an average daily volume of 133,900 shares, the days-to-cover ratio is presently 3.7 days. Approximately 2.6% of the company's shares are sold short.
View Acutus Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AFIB earnings forecast.

Acutus Medical, Inc. (NASDAQ:AFIB) issued its quarterly earnings results on Thursday, March, 16th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $1.11. The firm had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.80 million. Acutus Medical had a negative trailing twelve-month return on equity of 23.58% and a negative net margin of 94.43%.

Acutus Medical issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $19.00 million-$21.00 million, compared to the consensus revenue estimate of $19.64 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acutus Medical investors own include Oak Street Health (OSH), Alibaba Group (BABA), Checkmate Pharmaceuticals (CMPI), Salesforce (CRM), Walt Disney (DIS), DocuSign (DOCU), Marvell Technology (MRVL), NVIDIA (NVDA), Tesla (TSLA) and Twilio (TWLO).

(AFIB) raised $126 million in an IPO on Thursday, August 6th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Acutus Medical trades on the NASDAQ under the ticker symbol "AFIB."

Acutus Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.36%), Schonfeld Strategic Advisors LLC (0.59%), Cerity Partners LLC (0.22%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include James F Hinrichs, Orbimed Advisors Llc and R Scott Huennekens.
View institutional ownership trends.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFIB stock can currently be purchased for approximately $0.85.

Acutus Medical (NASDAQ:AFIB) has a market capitalization of $24.51 million and generates $16.85 million in revenue each year. The company earns $-39,620,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

The company employs 291 workers across the globe.

Acutus Medical's mailing address is 2210 FARADAY AVE SUITE 100, CARLSBAD CA, 92008. The official website for the company is www.acutusmedical.com. The company can be reached via phone at 442-232-6080, via email at investors@acutusmedical.com, or via fax at 442-232-6081.